Proton Therapy Falls Short Against Photons in Liver Cancer Survival Trial
A randomized trial finds photon radiotherapy doubles overall survival vs. proton therapy in hepatocellular carcinoma, upending expectations.
Summary
A major multicenter randomized trial called NRG-GI003 tested whether proton therapy outperforms photon radiation in locally advanced liver cancer. Surprisingly, patients receiving photon radiotherapy lived more than twice as long — a median of 54.9 months versus 26.6 months with protons. Progression-free survival and local tumor control were similar between groups. Protons did reduce radiation exposure to healthy tissue, resulting in lower severe toxicity rates. Researchers suspect improved systemic therapies, especially immune checkpoint combinations, boosted the photon arm beyond what was anticipated when the trial was designed. Experts noted the result challenges the assumption that proton therapy is always superior and calls for smarter patient selection — particularly understanding who might still benefit from proton's dosimetric precision.
Detailed Summary
Liver cancer — specifically hepatocellular carcinoma — remains one of the deadliest cancers worldwide, and it disproportionately affects older adults with underlying liver disease. Finding the most effective radiation strategy matters not just for cancer survival but for preserving the residual liver function that governs long-term quality of life and healthspan.
The NRG-GI003 randomized trial, presented at the ASTRO annual meeting, pitted proton therapy against photon radiotherapy in patients with locally advanced hepatocellular carcinoma. The headline result was striking: photon-treated patients survived a median of 54.9 months compared to just 26.6 months for those receiving protons — more than twice the overall survival. The finding was the opposite of what investigators hypothesized when the trial was designed.
Importantly, progression-free survival and rates of local tumor progression were statistically equivalent between the two treatment arms, suggesting the survival gap may not be explained by differences in local tumor control alone. Proton therapy did demonstrate a dosimetric advantage — meaningfully reducing radiation exposure to uninvolved liver tissue — and this translated into numerically fewer cases of severe toxicity. Yet this biological benefit did not convert to a survival edge.
Experts believe the photon arm's outperformance reflects rapid advances in systemic therapy, particularly immune checkpoint inhibitor combinations, adopted during the trial period. A subgroup analysis flagged tumor size as a potentially important modifier: photon therapy dramatically outperformed protons for tumors 5 cm or larger, though the reason for this interaction is unclear.
The trial also raised questions about dose escalation — only 58% of proton patients reached the highest planned dose level. Discussants urged researchers to explore whether proton therapy could expand treatment eligibility for high-risk patients rather than compete head-to-head with photons in similar populations. The results reinforce that modern liver radiation, in any form, is both effective and safe.
Key Findings
- Photon radiotherapy yielded a median overall survival of 54.9 months vs. 26.6 months for proton therapy in liver cancer.
- Progression-free survival and local tumor progression rates were similar between photon and proton arms.
- Proton therapy reduced radiation to healthy liver tissue but this dosimetric advantage did not translate into better survival.
- Photons dramatically outperformed protons for larger tumors (≥5 cm), an unexpected finding warranting further study.
- Only 58% of proton patients reached the highest radiation dose level, limiting the arm's potential efficacy.
Methodology
This is a meeting coverage news report summarizing results from NRG-GI003, a multicenter randomized controlled trial presented at the ASTRO 2026 annual meeting. The trial compared proton versus photon radiotherapy with an isotoxic design in locally advanced hepatocellular carcinoma. Full peer-reviewed publication has not yet been cited, so data should be considered preliminary conference findings.
Study Limitations
Results are from a conference presentation and have not yet undergone full peer-reviewed publication, limiting ability to assess methodology and statistical details. The survival difference may partly reflect imbalances in concurrent systemic therapy use rather than radiotherapy modality alone. Dose-escalation shortfalls in the proton arm may have disadvantaged that group, complicating direct comparison.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: